Published On: January 17, 2022Categories: Company news

The spin-off co-founded by María de la Fuente, Abi Judit Vázquez and Rafael López, participated by the Health Research Institute of Santiago de Compostela (IDIS) and the Galician Healthcare System (SERGAS), and incorporated in January 2022, goes to market with the aim of commercializing its technology for the release of drugs and biomolecules, to advance the development of innovative drugs that provide solutions to unmet medical needs.

The company’s business model includes three complementary avenues:

  • The commercialization of “ready-to-use” delivery kits for research and CROs with interest in testing their drugs/bimolecules of interest in their models in a first proof-of-concept.
  • The establishment of co-development agreements for new products with third party pharma & biotech companies that have a drug/biomolecule candidate and need an advanced formulation to bring them to the clinic.
  • The development of nanomedicines in the therapeutic areas of interest, oncology, metabolic, and autoimmune and inflammatory diseases.

DIVERSA was supported by the Ignicia program of the Xunta de Galicia (Axencia Galega de Innovación) and has been awarded with an IGAPE grant for new entrepreneurs, co-financed by the European Union and FEDER Galicia Funds 2014-2020 “Unha maneira de facer Europa”. The spin-off also participated in the first call of the high-tech incubator BioIncubaTech, specialized in the transfer of biotechnology applied to health and food, of the University of Santiago, funded by the Incyde Foundation, in collaboration with the Chamber of Commerce of Santiago and Uninova, as well as in other initiatives such as the accelerator SPIN-UP, the HealthTechTab program of the European Technology Platform in Nanomedicine, and other promoted by BIOGA.

DIVERSA’s main motivation is to bridge the gap between drug discovery and medical application, and to contribute to providing solutions to patients that have no adequate treatments for their diseases. By making use of their patented and versatile technology DIVERSA is geared up to initiate a therapeutic revolution.